Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

Trial Profile

Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Decitabine (Primary) ; Vemurafenib (Primary) ; Cobimetinib
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Acronyms ML28604
  • Most Recent Events

    • 03 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
    • 09 Jul 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2017.
    • 30 Dec 2015 According to ClinicalTrials.gov record, an additional drug cobimetinib has been included in this trial. This study will now examine the efficacy of vemurafenib administered in combination with decitabine plus cobimetinib.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top